Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BIVDA (British In Vitro Diagnostics Association) puts asthma drive atop UK agenda:

This article was originally published in Clinica

Executive Summary

The British In Vitro Diagnostics Association (BIVDA) is urging greater access to testing for asthma, in order to ensure the earliest possible diagnosis of the condition and improve prevention. BIVDA used World Asthma Day (May 6) to criticise the UK government's lack of impetus in addressing the problem. Asthma has a high health and social burden, accounting for 1-2% of the healthcare budget of industrialised countries. There were some 74,000 hospital admissions in the UK in 1999, says BIVDA. Of the 330,000 patients attended annually by each average primary care organisation in the UK, some 45,000 are diagnosed with asthma and 440 are admitted as emergency cases. Its prevalence is on the increase, with some estimates suggesting that the number of cases has doubled in the EU in the last 10 years.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT062041

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel